Drugs / MSCs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02083718 | Jan 2014 → Jan 2016 | disease related to hematopoietic stem cell transplant, hematologic disorder | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02083718 ↗ |
| Modality | Cell therapy | “Mesenchymal stem cells (MSCs) are a form of multipotent adult stem cells” NCT02083718 ↗ |
| Route | Intravenous | “MSCs will be intravenously infused” NCT02083718 ↗ |